Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
| ▸ | USP1 | O94782 | 2/20 | 0.37 |
| ▸ | WDR48 | Q8TAF3 | 2/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7064438 | 0.77 | CYP1A2 (0.49) | CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL13073855 | 0.71 | PTPN11 (0.55) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL3613286 | 0.69 | CYP2A6 (1.00) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL7061205 | 0.68 | RAB9A (0.40) | — | |
| SCHEMBL28415042 | 0.68 | CYP2A6 (0.61) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL7063618 | 0.68 | HDAC3 (0.35) | CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL7110560 | 0.68 | LMNA (0.35) | — | |
| SCHEMBL3607722 | 0.66 | CHRNB2 (0.64) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL7052162 | 0.66 | CYP2A6 (0.68) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL5376058 | 0.66 | CHRNB2 (0.58) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070544-A1 | 1,2,5,10-tetrahydropyridazino{4,5-b}quinoline-1,10-diones and their use for the treatment of pain | ASTRAZENECA AB | 2005-03-31 | — | — | US | disclosed |
| EP-1325005-A1 | 1,2,5,10-TETRAHYDROPYRIDAZINO 4,5-B]QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002026739-A1 | 1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-B]QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070544-A1 | 1,2,5,10-tetrahydropyridazino{4,5-b}quinoline-1,10-diones and their use for the treatment of pain | OPRD1, OPRK1, ACHE | CHRNB2 206/4885CHRNA4 93/4885CYP2A6 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.